Smegmatis Tuberculosis Drugs | OMICS International | Mycobacterial Diseases

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Smegmatis Tuberculosis Drugs

mycobacterium smegmatis is used for laboratory experiment purposes to aquire knowledge about all the other mycobacterium species. Treatment of TB requires multi-drug therapy comprising; an initial intensive phase of rifampicin, isoniazid, pyrazinamide, and ethambutol daily for two months and a continuation phase of rifampicin and isoniazid for a further 4 months, either daily or 3 times a week. Scholarly open access journals have emerged as an alternative to traditional subscription journals. Open access scholarly journals are available online to the reader without financial, legal, or technical barriers. Scholarly open access journals are journals which are respected for the extensive research and information they provide about the point. The research often possesses refereed meaning that it is reviewed by other scientists who are knowledgeable about the theme of the article. Apart from providing a free access to articles to everyone, it also extends support to other scholarly journals in the peer-review process, production, and distribution. All the articles published in OMICS Group journals are peer reviewed and published only on adhering to the norms.
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger

Last date updated on May, 2021